Premium
Anti‐osteoporotic effects of silibinin and silymarin and on osteoblast differentiation and RANKL‐dependent osteoclast differentiation
Author(s) -
Kim JungLye,
Choi JungSuk,
Oh SeonMi,
Kang YoungHee
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.946.5
Subject(s) - rankl , osteoclast , silibinin , chemistry , osteoblast , bone resorption , alkaline phosphatase , osteoporosis , cancer research , resorption , silybum marianum , medicine , endocrinology , biochemistry , activator (genetics) , traditional medicine , enzyme , in vitro , gene
Bone‐remodeling imbalance induced by increased bone resorption and osteoclast formation is known to cause skeletal diseases such as osteoporosis. Silibinin (SB) is the major active constituent of silymarin (SM), the mixture of flavonolignans extracted from blessed milk thistle. Several studies suggest that SB is a powerful antioxidant and has antihepatotoxic properties and anti‐cancer effects against carcinoma cells. This study investigated that SB and SM had anti‐osteoporotic effects. Murine macrophages were pre‐incubated with 10 μM SB and SM for 5 d in presence of RANKL. Non‐toxic SB inhibited RANKL‐mediated expression of TRAP in mature osteoclasts. In addition, SB markedly attenuated gelatinolytic MMP‐9 activity elevated by RANKL. SB suppressed the formation of multi‐nucleated osteoclasts, which was also observed by SM. Furthermore, MC3T3‐E1 mouse cells were treated with SB and SM for 14 d in a differentiate medium. It was found that SB and SM had a significant induction of osteoblast proliferation and differentiation. Additionally, alkaline phosphatase activity and matrix mineralization were enhanced with SB and SM, as determined by von Kossa and Alizarin red stainings. These results demonstrate that SB and SM were potential therapeutic agents for the prevention osteoporosis. Supported by the Regional Research Universities Program/Medical & Bio‐Materials Research Center.